Vantage Market Research.png
Atrial Fibrillation Market Size & Share to Surpass $38.9 Billion by 2028 | Vantage Market Research
27 mars 2023 09h27 HE | Vantage Market Research
WASHINGTON, March 27, 2023 (GLOBE NEWSWIRE) -- The global Atrial Fibrillation Market was valued at USD 17.5 Billion in 2022 and is projected to reach a value of USD 38.9 Billion by 2030 at a CAGR...
logo 600X600.png
Global Heparin Calcium Market to Surpass US$ 1,700.8 Million by 2030, Says Coherent Market Insights (CMI)
15 févr. 2023 09h15 HE | CMI
Burlingame, Feb. 15, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global heparin calcium market is estimated to be valued at US$ 1,370.9 in 2022 and is expected to exhibit a...
Holter ECG Market Size Report ($1.21 Billion by 2028) Driven by Rising Prevalence of CVDs – Exclusive Report by The Insight Partners
06 févr. 2023 08h36 HE | The Insight Partners
New York, Feb. 06, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Holter ECG Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by...
Global Atrial Fibrillation Market Report 2022 to 2028: Increasing Prevalence of Obesity and Cardiac Disorders Drives Growth
19 janv. 2023 04h03 HE | Research and Markets
Dublin, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The "Global Atrial Fibrillation Market Size, Share & Industry Trends Analysis Report by End-user, Type, Technology, Regional Outlook and Forecast,...
Anthos Logo Transparent.png
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
03 janv. 2023 08h00 HE | Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...
Global Atrial Fibrillation Treatment Market
Outlook on the Atrial Fibrillation Treatment Global Market to 2027 - Rising Prevalence of Cardiovascular Diseases Drives Growth
22 déc. 2022 06h38 HE | Research and Markets
Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Left Atrial Appendage Closure Devices Market worth USD 4.5 Billion by 2032, says Global Market Insights Inc.
21 nov. 2022 05h40 HE | Global Market Insights Inc.
Selbyville, Delaware, Nov. 21, 2022 (GLOBE NEWSWIRE) -- The left atrial appendage closure devices market value is set to surpass USD 4.5 billion by 2032, according to a recent report by Global...
InCarda Logo.png
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
07 nov. 2022 07h00 HE | InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
InCarda Logo.png
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
04 oct. 2022 07h00 HE | InCarda Therapeutics, Inc.
Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as...
S4 Medical
S4 Medical Meets Primary Endpoint in Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF Study)
12 sept. 2022 07h30 HE | S4 Medical Corp
CLEVELAND, Sept. 12, 2022 (GLOBE NEWSWIRE) -- S4 Medical Corp, an Ohio-based company with technology originating from The Ohio State University, announced that it is stopping the Esophagus Deviation...